国产日产欧美精品-亚洲国产综合久久精品-色综合色国产热无码一-亚洲欧美日本国产,免费观看一区二区三区_在线观看片A免费不卡观看_亚洲а∨天堂久久精品_99久无码中文字幕一本久道

青旗(上海)生物技術(shù)發(fā)展有限公司
中級會員 | 第5年

4006560232

當(dāng)前位置:青旗(上海)生物技術(shù)發(fā)展有限公司>>細胞庫>>細胞系>> 人肺腺癌細胞PC-9

人肺腺癌細胞PC-9

參  考  價面議
具體成交價以合同協(xié)議為準(zhǔn)

產(chǎn)品型號

品       牌其他品牌

廠商性質(zhì)生產(chǎn)商

所  在  地上海市

更新時間:2021-05-24 11:17:28瀏覽次數(shù):600次

聯(lián)系我時,請告知來自 化工儀器網(wǎng)
同類優(yōu)質(zhì)產(chǎn)品更多>
供貨周期 現(xiàn)貨 規(guī)格 T25培養(yǎng)瓶x1 1.5ml凍存管x2
貨號 BFN60800699 應(yīng)用領(lǐng)域 醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)
主要用途 僅供科研
青旗(上海)生物技術(shù)發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺,在標(biāo)準(zhǔn)化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細胞、細胞系、ELISA試劑盒、感受態(tài)細胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負責(zé)的態(tài)度,以對科研的高度嚴謹,以嚴格的質(zhì)量控制,為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)!

細胞名稱

人肺腺癌細PC-9                  

img1

貨物編碼

BFN60800699

產(chǎn)品規(guī)格

T25培養(yǎng)x1

1.5ml凍存x2

細胞數(shù)量

1x10^6

1x10^6

保存溫度

37

-198

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研用途              1類

 

培養(yǎng)體系

DMEM高糖培養(yǎng)基Hyclone+10%胎牛血清Gibco+1%雙抗Hyclone

培養(yǎng)溫度

37

二氧化碳濃度

5%

簡介

人肺腺癌細PC-9 1989年取自一位日本人肺癌組織。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: MD Anderson Cell Lines Project.

From: Immuno-Biological Laboratories (IBL); Tokyo; Japan.

Omics: Deep exome analysis.

Omics: Deep membrane proteome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep RNAseq analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

STR信息

Amelogenin        X

CSF1PO        11

D2S1338        19,20

D3S1358        16

D5S818        11

D7S820        10,11

D8S1179        11,15

D13S317        8

D16S539        9

D18S51        15

D19S433        13,15.2

D21S11        30

FGA        23

Penta D        13

Penta E        11

TH01        7

TPOX        11

vWA        17

參考文獻

DOI=10.5795scc.24.451

Tsumuraya M., Nakajima T., Terasaki T., Kodama T., Shimosato Y., Higuchi H., Uei Y.

Analysis of LDH isoenzyme patterns in cell lines of the small cell carcinoma (lung) and retinoblastoma.

Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985)

 

PubMed=4094096

Lee Y.-C., Saijo N., Sasaki Y., Takahashi H., Sakurai M., Ishihara J., Hoshi A., Chen K.-M., Hamburger A.W.

Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay.

Jpn. J. Clin. Oncol. 15:637-644(1985)

 

PubMed=1847845; DOI=10.1007/BF00685110

Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T., Saijo N.

Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Cancer Chemother. Pharmacol. 27:263-270(1991)

 

PubMed=1737336

Yoshino I., Yano T., Murata M., Ishida T., Sugimachi K., Kimura G., Nomoto K.

Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor.

Cancer Res. 52:775-781(1992)

 

PubMed=9023415; DOI=10.1006/cimm.1996.1062

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Cell. Immunol. 175:101-110(1997)

 

PubMed=9178645; DOI=10.1006/cimm.1997.1108

Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.

CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.

Cell. Immunol. 177:176-181(1997)

 

PubMed=11005564; DOI=10.1038/sj.neo.7900094

Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J.

Mutation and expression of the DCC gene in human lung cancer.

Neoplasia 2:300-305(2000)

 

PubMed=11078804; DOI=10.3892/ijo.17.6.1187

Takenaka K., Shibuya M., Takeda Y., Hibino S., Gemma A., Ono Y., Kudoh S.

Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line.

Int. J. Oncol. 17:1187-1194(2000)

 

PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331

Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

Cancer Res. 65:7276-7282(2005)

 

PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339

Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., Nakagawa K.

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

Cancer Res. 67:2046-2053(2007)

 

PubMed=17511773; DOI=10.1111/j.1349-7006.2007.00507.x

Fukuyama T., Ichiki Y., Yamada S., Shigematsu Y., Baba T., Nagata Y., Mizukami M., Sugaya M., Takenoyama M., Hanagiri T., Sugio K., Yasumoto K.

Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro.

Cancer Sci. 98:1048-1054(2007)

 

PubMed=19472407; DOI=10.1002/humu.21028

Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

A gene-alteration profile of human lung cancer cell lines.

Hum. Mutat. 30:1199-1206(2009)

 

PubMed=19799608; DOI=10.1111/j.1349-7006.2009.01351.x

Kuroda K., Takenoyama M., Baba T., Shigematsu Y., Shiota H., Ichiki Y., Yasuda M., Uramoto H., Hanagiri T., Yasumoto K.

Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cytotoxic T lymphocytes in lung adenocarcinoma.

Cancer Sci. 101:46-53(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=22313637; DOI=10.4161/cbt.19238

Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A., Igishi T., Burioka N., Nanba E., Shimizu E.

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.

Cancer Biol. Ther. 13:369-378(2012)

 

PubMed=23733853; DOI=10.1101/gr.152322.112

Jia P., Jin H., Meador C.B., Xia J., Ohashi K., Liu L., Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z., Pao W.

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.

Genome Res. 23:1434-1445(2013)

 

PubMed=26202522; DOI=10.1021/acs.jproteome.5b00477

Kitata R.B., Dimayacyac-Esleta B.R., Choong W.-K., Tsai C.-F., Lin T.-D., Tsou C.-C., Weng S.-H., Chen Y.-J., Yang P.-C., Arco S.D., Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.

Mining missing membrane proteins by high-pH reverse-phase stagetip fractionation and multiple reaction monitoring mass spectrometry.

J. Proteome Res. 14:3658-3669(2015)

 

PubMed=26554430; DOI=10.1021/acs.analchem.5b03639

Dimayacyac-Esleta B.R., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K., Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y., Chen Y.-J.

Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.

Anal. Chem. 87:12016-12023(2015)

 

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

 

PubMed=28290473; DOI=10.1038ep44021

Wang Y.-T., Pan S.-H., Tsai C.-F., Kuo T.-C., Hsu Y.-L., Yen H.-Y., Choong W.-K., Wu H.-Y., Liao Y.-C., Hong T.-M., Sung T.-Y., Yang P.-C., Chen Y.-J.

Phosphoproteomics reveals HMGA1, a CK2 substrate, as a drug-resistant target in non-small cell lung cancer.

Sci. Rep. 7:44021-44021(2017)

 

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

 

 

驗收細胞注意事 

1、收到人肺腺癌細PC-9細胞,請查看瓶子是否有破裂,培養(yǎng)基是否漏出,是否渾濁,如有請盡快聯(lián)系。 

2、收到人肺腺癌細PC-9細胞,如包裝完好,請在顯微鏡下觀察細胞,由于運輸過程中的問題,細胞培養(yǎng)瓶中的貼壁細胞有可能從瓶壁中脫落下來,顯微鏡下觀察會出現(xiàn)細胞懸浮的情況,出現(xiàn)此狀態(tài)時,請不要打開細胞培養(yǎng)瓶,應(yīng)立即將培養(yǎng)瓶置于細胞培養(yǎng)箱里靜 3-5 小時左右,讓細胞先穩(wěn)定下,再于顯微鏡下觀察,此時多數(shù)細胞會重新貼附于瓶壁。如細胞仍不能貼壁,請用臺盼藍染色法鑒定細胞活力,如臺盼藍染色證實細胞活力正常請按懸浮細胞的方法處理。 

3、收到人肺腺癌細PC-9細胞后,請鏡下觀察細胞,用恰當(dāng)方式處理細胞。若懸浮的細胞較多,請離心收集細胞,接種到一個新的培養(yǎng)瓶中。棄掉原液,使用新鮮配制的培養(yǎng)基,使用進口胎牛血清。剛接到細胞,若細胞不多 血清濃度可以加 15%去培養(yǎng)。若細胞迏 80% ,血清濃度還是 10 

4、收到人肺腺癌細PC-9細胞時如無異常情 ,請在顯微鏡下觀察細胞密度,如為貼壁細胞,未超80%匯合度時,將培養(yǎng)瓶中培養(yǎng)基吸出,留 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng):超 80%匯合度時,請按細胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細胞,吸出培養(yǎng)液,1000 轉(zhuǎn)/分鐘離 3 分鐘,吸出上清,管底細胞用新鮮培養(yǎng)基懸浮細胞后移回培養(yǎng)瓶。 

5、將培養(yǎng)瓶置 37培養(yǎng)箱中培養(yǎng),蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里,存放 4冰箱,以備不時之需。 

6、24 小時后,人肺腺癌細PC-9細胞形態(tài)已恢復(fù)并貼滿瓶壁,即可傳代。(貼壁細胞)將培養(yǎng)瓶里的培養(yǎng)基倒去, 3-5ml(以能覆蓋細胞生長面為準(zhǔn)PBS  Hanks液洗滌后棄去。 0.5-1ml 0.25% EDTA 的胰酶消化,消化時間以具體細胞為準(zhǔn),一 1-3 分鐘,不超 5 分鐘??梢苑?/span>37培養(yǎng)箱消化。輕輕晃動瓶壁,見細胞脫落下來,加 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細胞,使之*脫落,然后將溶液吸入離心管內(nèi)離心,1000rpm/5min。棄上清,視細胞數(shù)量決定分瓶數(shù),一般一傳二,如細胞量多可一傳三,有些細胞不易傳得過稀,有些生長較快的細胞則可以多傳幾瓶,以具體細胞和經(jīng)驗為準(zhǔn)。(懸浮細胞)用移液管輕輕吹打瓶壁,直接將溶液吸入離心管離心即可。 

7、貼壁細 ,懸浮細胞。嚴格無菌操作。換液時,換新的細胞培養(yǎng)瓶和換新鮮的培養(yǎng)液37,5%CO2 培養(yǎng)。

 

特別提醒 原瓶中培養(yǎng)基不宜繼續(xù)使用,請更換新鮮培養(yǎng)基培養(yǎng)。

會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

X
該信息已收藏!
標(biāo)簽:
保存成功

(空格分隔,最多3個,單個標(biāo)簽最多10個字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時間回復(fù)您~
撥打電話
在線留言
绥棱县| 连南| 贡嘎县| 玉屏| 梁平县| 宁乡县| 陆良县| 鹤庆县| 无锡市| 永济市| 延吉市| 莱阳市| 苏州市| 乌鲁木齐市| 临沂市| 岳西县| 黄浦区| 肥乡县| 长岛县| 合江县| 临泽县| 常州市| 邛崃市| 乌审旗| 上饶县| 大荔县| 大姚县| 万荣县| 车险| 全州县| 蓬安县| 巴南区| 贺兰县| 光泽县| 台湾省| 神农架林区| 乌兰察布市| 广州市| 湘潭县| 阿拉善右旗| 卢龙县|